Jan 22,2024

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024

Tandem Diabetes Care plans to release its fourth quarter and full year 2023 results after the financial markets close on Wednesday, February 21, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2023 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Jan 23,2024

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

DexCom announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

View Analyst & Ambassador Comments
Go to original news
Jan 23,2024

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

Eli Lilly and Company will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.

View Analyst & Ambassador Comments
Go to original news
Jan 11,2024

Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Insulet Corporation announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jan 14,2024 TOP STORY

FDA seeks feedback on digital tools for diabetes

The FDA has opened a comment period, extending until the end of the month, that is seeking information on how digital health technologies (DHTs) might be deployed to help prevent, detect, and manage diabetes. The call has gone out from Troy Tazbaz, the ex-Oracle executive who was recently appointed director of the FDA’s Digital Health Centre of Excellence, (DHCoE). The consultation is asking how DHTs can extend care into people’s homes and communities, play a role in early detection and prevention of the disease, and potentially even help to reverse type 2 diabetes. It also wants to hear how they might be used to prevent some of the common complications of diabetes, such as blindness, peripheral nerve damage, and cardiovascular and kidney diseases. ''... the full potential of DHTs for the detection of prediabetes and undiagnosed diabetes, especially in diverse populations, particularly racial and ethnic minorities, has yet to be realised.” said Tazbaz.

View Analyst & Ambassador Comments
Go to original news
Jan 17,2024 TOP STORY

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Better Therapeutics announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy peer-reviewed medical journal. This latest study modeled the cost-effectiveness of AspyreRx plus standard of care (SoC) versus SoC alone in T2D over a lifetime horizon. From a healthcare payer perspective, AspyreRx plus SoC versus SoC alone was dominant because AspyreRx was associated both with gains in quality-adjusted life years (QALYs) and cost savings of $7,343 per patient over the lifetime horizon. AspyreRx plus SoC was cost-effective at a willingness-to-pay of $100,000 per QALY over SoC alone, with an incremental net monetary benefit (INMB) of $17,443. At other commonly applied thresholds of $50,000 and $150,000 per QALY, the study yielded INMBs of $12,393 and $22,493, respectively. Savings were primarily driven by a reduction in drug costs, followed by reductions in adverse event costs.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Jan 17,2024

Hygieia and TempraMed Announce Partnership

Hygieia, a digital health company for insulin therapy announces a new partnership with TempraMed, a manufacturer of advanced temperature-based insulin storage solutions. Hygieia’s d-Nav® technology is the first FDA-cleared AI-driven system that autonomously adjusts insulin doses based on the unique needs of its user. This enables more frequent and optimal dose adjustments to better manage glucose levels. In addition to the app which handles dosing, d-Nav users are supported by a team of expert clinicians who review patient data and stay in frequent communication. TempraMed’s flagship product, the VIVI Cap, is a FDA- cleared and CE-Marked insulin temperature shield pen cap and designed for those who use insulin and/or weight loss medications. The VIVI Cap ensures medication efficacy by maintaining optimal temperatures.

COLLABORATION PARTNERSHIP

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 15,2024

Patients with diabetes need more than glucose monitoring systems

Patients with diabetes increasingly use continuous glucose monitoring systems (CGMs), but Arti Masturzo of CCS, a chronic care management company, emphasizes that technology alone is insufficient. In an interview, Masturzo highlights the importance of education and support for patients and providers. She discusses the 2023 guidelines from the American Diabetes Association, noting that only half of CGM users receive diabetes education. Masturzo suggests personalized care, combining CGMs with education and coaching, to simplify diabetes management. She also addresses the role of primary care providers, the need for ongoing support, and challenges in underserved communities. Additionally, Masturzo emphasizes the importance of clinician training to ensure accurate CGM usage and overall diabetes care.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 11,2024 TOP STORY

A new prescription app against Type 2 Diabetes

Developed by Perfood GmbH, Glucura type 2 diabetes therapy app has been added provisionally to the DiGA list in Germany, making it available for prescriptions in the country. Approved by the Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA), glucura utilizes individual glucose reactions to provide personalized nutrition recommendations for individuals with Type 2 diabetes. Using artificial intelligence, users receive tailored lifestyle recommendations to effectively and sustainably lower their blood sugar levels. A clinical study demonstrated a significant improvement in long-term blood sugar levels (HbA1c) after three months of glucura usage compared to standard treatment. Users can also export their data for sharing with healthcare professionals, contributing to a holistic approach in diabetes care. The app will be available in the DiGA until January 2025.

PRODUCT

#reimbursement

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES